{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:28:02Z","timestamp":1784906882534,"version":"3.55.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"6 October University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Felodipine (FEL), an antihypertensive drug, is being repurposed as an anticancer drug. It has low oral bioavailability due to its extensive metabolism in the liver and poor water solubility. This study aimed to develop hyaluronic acid-coated cetylosomes (HCCs) for parenteral delivery of FEL to boost its solubility and anticancer efficacy. FEL-HCCs were prepared by the thin-film hydration technique based on Box-Behnken design. Amounts of cetyl alcohol, Brij 97, and hyaluronic acid were the independent factors. The optimized HCC (OHCC) formula which showed the highest desirability value (0.626), was composed of 100 mg Brij 97, 32.44 mg CA, and 10 mg HA. It showed the minimum vesicle size (156.72 nm) and polydispersity index (0.134), and the maximum entrapment efficiency% (72.04%) and zeta potential (-30.58 mV). After lyophilization and sterilization of the OHCC formula, it showed a 2.01-fold enhancement in FEL release compared to the market tablet, with no significant difference in release before and after lyophilization or sterilization. The sterilized OHCC was stable for six months. The OHCC showed an enhanced cytotoxicity against MCF-7 cells with 6.61-fold compared to pure FEL powder. Additionally, the OHCC potentiated the antiproliferative effect of doxorubicin, as evidenced by a raised Bax\/Bcl-2 ratio and caspase 9 content, and suppressed VEGF levels. In vivo\n                    <jats:italic>,<\/jats:italic>\n                    the OHCC markedly reduced tumor growth, particularly in combination with doxorubicin. The histopathological investigation supported the apoptotic and necrotic death of cancer cells. These findings suggest that HCCs represent a promising nanocarrier system for the targeted parenteral delivery of FEL in cancer therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-026-02090-0","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:01:50Z","timestamp":1775487710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repurposing felodipine via hyaluronic acid-coated cetylosomes (HCCs) for parenteral active targeting of cancer: Box-Behnken statistical optimization, in vitro characterization, and in vivo studies"],"prefix":"10.1007","author":[{"given":"Rania Moataz","family":"El-Dahmy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaz A.","family":"Eltabeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"Fayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad Z.","family":"El-Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagwa M. El","family":"Adl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona M.","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman M.","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"2090_CR1","doi-asserted-by":"crossref","first-page":"120202","DOI":"10.1016\/j.ijpharm.2021.120202","volume":"596","author":"AR Koli","year":"2021","unstructured":"Koli AR, Ranch KM, Patel HP, Parikh RK, Shah DO, Maulvi A. Oral bioavailability improvement of felodipine using tailored microemulsion\u202f: surface science , ex vivo and in vivo studies. Int J Pharm. 2021;596:120202.","journal-title":"Int J Pharm"},{"key":"2090_CR2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.aihch.2023.04.001","volume":"141","author":"RM Vala","year":"2023","unstructured":"Vala RM, Patel HM. Recent developments in the Hantzsch synthesis of dihydropyridines. Adv Heterocycl Chem. 2023;141:179\u2013208.","journal-title":"Adv Heterocycl Chem"},{"key":"2090_CR3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.matpr.2021.08.209","volume":"48","author":"HS Sohal","year":"2022","unstructured":"Sohal HS. A review on recent trends in synthesis and applications of 1,4-dihydropyridines Harvinder. Mater Today Proc J. 2022;48:1163\u201370.","journal-title":"Mater Today Proc J"},{"key":"2090_CR4","first-page":"1","volume":"21","author":"Y He","year":"2020","unstructured":"He Y, Zhan C, Pi C, Zuo Y, Yang S, Hu M, et al. Enhanced oral bioavailability of felodipine from solid lipid nanoparticles prepared through effervescent dispersion technique. AAPS PharmSciTech. 2020;21:1\u201310.","journal-title":"AAPS PharmSciTech"},{"key":"2090_CR5","doi-asserted-by":"crossref","first-page":"102053","DOI":"10.1016\/j.jddst.2020.102053","volume":"60","author":"DU Chavan","year":"2020","unstructured":"Chavan DU, Marques SM, Bhide PJ, Kumar L, Shirodkar RK. Rapidly dissolving Felodipine nanoparticle strips -formulation using design of experiment and characterisation. J Drug Deliv Sci Technol. 2020;60:102053.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2090_CR6","volume":"70","author":"AH Ibrahim","year":"2022","unstructured":"Ibrahim AH, Ibrahim HM, Elbahwy IA, Afouna MI, Tagami T, Ozeki T. Lyophilized tablets of felodipine-loaded polymeric nanocapsules to enhance aqueous solubility: formulation and optimization. J Drug Deliv Sci Technol. 2022;70: 103172.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2090_CR7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1567-5769(02)00271-0","volume":"3","author":"H Maeda","year":"2003","unstructured":"Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003;3:319\u201328.","journal-title":"Int Immunopharmacol"},{"key":"2090_CR8","doi-asserted-by":"crossref","first-page":"013075","DOI":"10.1103\/PhysRevResearch.2.013075","volume":"2","author":"TE De Oliveira","year":"2020","unstructured":"De Oliveira TE, Leonforte F, Nicolas-Morgantini L, Fameau AL, Querleux B, Thalmann F, et al. Fluid bilayer phase in aqueous mixtures of fatty alcohol and cationic surfactant. Phys Rev Res. 2020;2:013075.","journal-title":"Phys Rev Res"},{"key":"2090_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/pharmaceutics11060275","volume":"11","author":"I Elsayed","year":"2019","unstructured":"Elsayed I, El-Dahmy RM, Elshafeey AH, El Gawad NAA, El Gazayerly ON. Tripling the bioavailability of rosuvastatin calcium through development and optimization of an In-situ forming nanovesicular system. Pharmaceutics. 2019;11:275.","journal-title":"Pharmaceutics"},{"key":"2090_CR10","first-page":"1","volume":"12","author":"AM Nasr","year":"2020","unstructured":"Nasr AM, Elhady SS, Swidan SA, Badawi NM. Celecoxib loaded In-situ provesicular powder and its In-vitro cytotoxic effect for cancer therapy: fabrication, characterization, optimization and pharmacokinetic evaluation. Pharmaceutics. 2020;12:1\u201320.","journal-title":"Pharmaceutics"},{"key":"2090_CR11","volume":"655","author":"RM El-Dahmy","year":"2024","unstructured":"El-Dahmy RM, Elshafeey AH, El-Feky YA. Fabrication, optimization, and evaluation of lyophilized lacidipine-loaded fatty-based nanovesicles as orally fast disintegrating sponge delivery system. Int J Pharm. 2024;655: 124035.","journal-title":"Int J Pharm"},{"key":"2090_CR12","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-025-03299-x","volume":"27","author":"U Kafle","year":"2025","unstructured":"Kafle U, Moore E, Lushnikov A, Dash AK. Co-encapsulation of doxorubicin HCl and paclitaxel in nanovesicles for enhanced breast cancer therapy. AAPS PharmSciTech. 2025;27: 41.","journal-title":"AAPS PharmSciTech"},{"key":"2090_CR13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.colsurfb.2014.06.025","volume":"121","author":"J Park","year":"2014","unstructured":"Park J, Cho H, Termsarasab U, Lee J, Ko S, Shim J, et al. Colloids and Surfaces B\u202f: Biointerfaces Interconnected hyaluronic acid derivative-based nanoparticles for anticancer drug delivery. Colloids Surfaces B Biointerfaces. 2014;121:380\u20137.","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"2090_CR14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jconrel.2016.01.049","volume":"225","author":"W Li","year":"2016","unstructured":"Li W, Yi X, Liu X, Zhang Z, Fu Y, Gong T. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy. J Control Release. 2016;225:170\u201382.","journal-title":"J Control Release"},{"key":"2090_CR15","doi-asserted-by":"crossref","first-page":"107770","DOI":"10.1016\/j.jddst.2025.107770","volume":"115","author":"MA Tawfik","year":"2026","unstructured":"Tawfik MA, Abd-Elrasheed E, El-Dahmy RM, Eltaweel MM. Hyaluobilosomes (hyaluronic acid enriched bilosomes) as novel mucoadhesive prolonged release nanocarriers of felodipine for the treatment of glaucoma. J Drug Deliv Sci Technol. 2026;115:107770.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2090_CR16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2018.04.050","volume":"280","author":"HY Seok","year":"2018","unstructured":"Seok HY, Sanoj Rejinold N, Lekshmi KM, Cherukula K, Park IK, Kim YC. CD44 targeting biocompatible and biodegradable hyaluronic acid cross-linked zein nanogels for curcumin delivery to cancer cells: in vitro and in vivo evaluation. J Control Release. 2018;280:20\u201330.","journal-title":"J Control Release"},{"key":"2090_CR17","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.biomaterials.2011.10.064","volume":"33","author":"HJ Cho","year":"2012","unstructured":"Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, Ko SH, et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials. 2012;33:1190\u2013200.","journal-title":"Biomaterials"},{"key":"2090_CR18","doi-asserted-by":"crossref","first-page":"123637","DOI":"10.1016\/j.ijpharm.2023.123637","volume":"649","author":"NG Sallam","year":"2024","unstructured":"Sallam NG, Boraie NA, Sheta E, El-Habashy SE. Targeted delivery of genistein for pancreatic cancer treatment using hyaluronic-coated cubosomes bioactivated with frankincense oil. Int J Pharm. 2024;649:123637.","journal-title":"Int J Pharm"},{"key":"2090_CR19","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1039\/C9BM01927H","volume":"8","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhao M, Cao N, Qin W, Zhao M, Wu J, et al. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer. Biomater Sci. 2020;8:1885\u201396.","journal-title":"Biomater Sci"},{"key":"2090_CR20","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2217\/nnm-2018-0419","volume":"14","author":"DG Dastidar","year":"2019","unstructured":"Dastidar DG, Das A, Datta S, Ghosh S, Pal M, Thakur NS, et al. Paclitaxel-encapsulated core-shell nanoparticle of cetyl alcohol for active targeted delivery through oral route. Nanomedicine. 2019;14:2121\u201350.","journal-title":"Nanomedicine"},{"key":"2090_CR21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/03639040600640006","volume":"32","author":"X Dong","year":"2006","unstructured":"Dong X, Mumper RJ. The metabolism of fatty alcohols in lipid nanoparticles by alcohol dehydrogenase. Drug Dev Ind Pharm. 2006;32:973\u201380.","journal-title":"Drug Dev Ind Pharm"},{"key":"2090_CR22","first-page":"731","volume":"7","author":"P Lee","year":"2012","unstructured":"Lee P, Zhang R, Li V, Liu X, Sun RWY, Che M, et al. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine. 2012;7:731\u20137.","journal-title":"Int J Nanomedicine"},{"key":"2090_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118460","author":"VFM Carvalho","year":"2019","unstructured":"Carvalho VFM, Salata GC, de Matos JKR, Costa-Fernandez S, Chorilli M, Steiner AA, et al. Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting. Int J Pharm. 2019;567:\u00a0118460.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118460.","journal-title":"Int J Pharm"},{"key":"2090_CR24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejpb.2021.10.014","volume":"169","author":"WC Luo","year":"2021","unstructured":"Luo WC, O\u2019Reilly Beringhs A, Kim R, Zhang W, Patel SM, Bogner RH, et al. Impact of formulation on the quality and stability of freeze-dried nanoparticles. Eur J Pharm Biopharm. 2021;169:256\u201367.","journal-title":"Eur J Pharm Biopharm"},{"key":"2090_CR25","doi-asserted-by":"crossref","first-page":"107193","DOI":"10.1016\/j.jddst.2025.107193","volume":"111","author":"NM Sheta","year":"2025","unstructured":"Sheta NM, El-nabarawi MA, Gamal H, Abo-zalam HB, El-dahmy RM. Fabrication of PEGylated elastic bilosomes as a potentially effective transdermal delivery of celecoxib for management of osteoarthritis\u202f: in vitro characterization, statistical optimization, ex vivo and in vivo assessments. J Drug Deliv Sci Technol. 2025;111:107193.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2090_CR26","volume":"678","author":"RM El-Dahmy","year":"2025","unstructured":"El-Dahmy RM, El-Nabarawi MA, Mostafa HG, Salama A, Sheta NM. Role of chitosan coated invasomes in enhancement of transdermal delivery of tenoxicam for management of osteoarthritis: In vitro characterization, statistical optimization, ex vivo, and in vivo assessments. Int J Pharm. 2025;678: 125700.","journal-title":"Int J Pharm"},{"key":"2090_CR27","doi-asserted-by":"crossref","first-page":"1746918","DOI":"10.3389\/fphar.2025.1746918","volume":"16","author":"S Ahmed","year":"2026","unstructured":"Ahmed S, Saher O, Attia H, Fahmy AM, Adel IM. Innovative dual-functional hybrid cationic PEGylated proniosomes as a smart nano-platform for boosted vaginal delivery: multi-level in-vitro, ex-vivo, microbiological, and in-vivo studies. Front Pharmacol. 2026;16:1746918.","journal-title":"Front Pharmacol"},{"key":"2090_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12249-025-03250-0","volume":"27","author":"MA Tawfik","year":"2025","unstructured":"Tawfik MA, Ahmed S, El-Dahmy RM, Aziz DE. Oleic acid enriched leciplexes as novel mucoadhesive cationic nanocarriers of agomelatine for glaucoma treatment. AAPS PharmSciTech. 2025;27:4.","journal-title":"AAPS PharmSciTech"},{"key":"2090_CR29","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/10717544.2021.1989089","volume":"28","author":"R Albash","year":"2021","unstructured":"Albash R, Fahmy AM, Hamed MIA, Khaled MD, El-Dahmy RM, Fahmy AM. Spironolactone hyaluronic acid enriched cerosomes ( HAECs ) for topical management of hirsutism\u202f: in silico studies, statistical optimization, ex vivo, and in vivo studies. Drug Deliv. 2021;28:2289\u2013300.","journal-title":"Drug Deliv"},{"key":"2090_CR30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2014.10.003","volume":"477","author":"RM El-Dahmy","year":"2014","unstructured":"El-Dahmy RM, Elsayed I, Elshafeey AH, Abd El Gawad NA, El-gazayerly ON. Optimization of long circulating mixed polymeric micelles containing vinpocetine using simple lattice mixture design, in vitro and in vivo characterization. Int J Pharm. 2014;477:39\u201346.","journal-title":"Int J Pharm"},{"key":"2090_CR31","unstructured":"United States Pharmacopeial Convention. The United States Pharmacopeia: USP 30; The National Formulary: NF 25. United States Pharmacopeial Convention. 2006."},{"key":"2090_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107061","volume":"208","author":"R Albash","year":"2025","unstructured":"Albash R, Fahmy AM, Shamsel-Din HA, Ibrahim AB, Bogari HA, Malatani RT, et al. Intranasal propranolol hydrochloride-loaded PLGA-lipid hybrid nanoparticles for brain targeting: optimization and biodistribution study by radiobiological evaluation. Eur J Pharm Sci. 2025;208: 107061.","journal-title":"Eur J Pharm Sci"},{"key":"2090_CR33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.22159\/ijap.2020v12i3.37203","volume":"12","author":"K Trideva Sastri","year":"2020","unstructured":"Trideva Sastri K, Radha GV. Development of self nano-emulsifying drug delivery system for an anti-hypertensive agent felodipine: a systematic approach for lipid nano-formulation with improved oral bioavailability in rats. Int J Appl Pharm. 2020;12:86\u201394.","journal-title":"Int J Appl Pharm"},{"key":"2090_CR34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3109\/03639045.2013.819884","volume":"40","author":"S Verma","year":"2014","unstructured":"Verma S, Singh SK, Verma PRP, Ahsan MN. Formulation by design of felodipine loaded liquid and solid self nanoemulsifying drug delivery systems using Box-Behnken design. Drug Dev Ind Pharm. 2014;40:1358\u201370.","journal-title":"Drug Dev Ind Pharm"},{"key":"2090_CR35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0378-5173(02)00487-8","volume":"249","author":"JA Ko","year":"2002","unstructured":"Ko JA, Park HJ, Hwang SJ, Park JB, Lee JS. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int J Pharm. 2002;249:165\u201374.","journal-title":"Int J Pharm"},{"key":"2090_CR36","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s12247-023-09716-7","volume":"18","author":"S Sana","year":"2023","unstructured":"Sana S, Shirodkar RK, Kumar L, Verma R. Enhancement of solubility and dissolution rate using tailored rapidly dissolving oral films containing felodipine solid dispersion: in vitro characterization and ex vivo studies. J Pharm Innov. 2023;18:1241\u201352.","journal-title":"J Pharm Innov"},{"key":"2090_CR37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/pharmaceutics15041083","volume":"15","author":"RM El-Dahmy","year":"2023","unstructured":"El-Dahmy RM, Elsayed I, Hussein J, Althubiti M, Almaimani RA, El-readi MZ, et al. Development of transdermal oleogel containing olmesartan medoxomil\u202f: statistical optimization and pharmacological evaluation. Pharmaceutics. 2023;15:1083.","journal-title":"Pharmaceutics"},{"key":"2090_CR38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55\u201363.","journal-title":"J Immunol Methods"},{"key":"2090_CR39","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s13346-020-00761-0","volume":"10","author":"I Elsayed","year":"2020","unstructured":"Elsayed I, El-Dahmy RM, El-Emam SZ, Elshafeey AH, Abd El Gawad NA, El-gazayerly ON. Response surface optimization of biocompatible elastic nanovesicles loaded with rosuvastatin calcium\u202f: enhanced bioavailability and anticancer efficacy. Drug Deliv Transl Res. 2020;10:1459\u201375.","journal-title":"Drug Deliv Transl Res"},{"key":"2090_CR40","doi-asserted-by":"crossref","unstructured":"Strober W. Trypan Blue Exclusion Test of Cell Viability. Curr Protoc Immunol; 2015;111:A3.B.1\u2013A3.B.3.","DOI":"10.1002\/0471142735.ima03bs111"},{"key":"2090_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12659\/MSMBR.893327","volume":"21","author":"K Liu","year":"2015","unstructured":"Liu K, Liu P, Liu R, Wu X. Dual AO\/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med Sci Monit Basic Res. 2015;21:15\u201320.","journal-title":"Med Sci Monit Basic Res"},{"issue":"2","key":"2090_CR42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/cdd.2013.139","volume":"21","author":"D Westphal","year":"2013","unstructured":"Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ. 2013;21(2):196\u2013205.","journal-title":"Cell Death Differ"},{"key":"2090_CR43","volume":"19","author":"A Ghasemi","year":"2018","unstructured":"Ghasemi A, Khanzadeh T, Heydarabad MZ, Khorrami A, Esfahlan AJ, Ghavipanjeh S, et al. Evaluation of BAX and BCL-2 gene expression and apoptosis induction in acute lymphoblastic leukemia cell line CCRF-CEM after high- dose prednisolone treatment. Asian Pac J Cancer Prev. 2018;19: 2319.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2090_CR44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.701301","volume":"12","author":"MI Avrutsky","year":"2021","unstructured":"Avrutsky MI, Troy CM. Caspase-9: a multimodal therapeutic target with diverse cellular expression in human disease. Front Pharmacol. 2021;12: 1728.","journal-title":"Front Pharmacol"},{"key":"2090_CR45","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.7150\/thno.43622","volume":"10","author":"G Zou","year":"2020","unstructured":"Zou G, Zhang X, Wang L, Li X, Xie T, Zhao J, et al. Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics. 2020;10:6839\u201353.","journal-title":"Theranostics"},{"key":"2090_CR46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000346201","volume":"20","author":"JMR Maragno-Correa","year":"2013","unstructured":"Maragno-Correa JMR, Patti CL, Zanin KA, Wuo-Silva R, Ruiz FS, Zager A, et al. Sleep deprivation increases mortality in female mice bearing Ehrlich ascitic tumor. NeuroImmunoModulation. 2013;20:134\u201340.","journal-title":"NeuroImmunoModulation"},{"key":"2090_CR47","doi-asserted-by":"crossref","DOI":"10.1007\/s12291-013-0343-y","volume":"29","author":"R Kapoor","year":"2014","unstructured":"Kapoor R, Gundpatil DB, Somani BL, Saha TK, Bandyopadhyay S, Misra P. Anticancer effect of dl-glyceraldehyde and 2-deoxyglucose in Ehrlich ascites carcinoma bearing mice and their effect on liver, kidney and haematological parameters. Indian J Clin Biochem. 2014;29: 213.","journal-title":"Indian J Clin Biochem"},{"key":"2090_CR48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4103\/0253-7613.84952","volume":"43","author":"AHM Viswanatha Swamy","year":"2011","unstructured":"Viswanatha Swamy AHM, Wangikar U, Koti BC, Thippeswamy AHM, Ronad PM, Manjula DV. Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats. Indian J Pharmacol. 2011;43:507\u201311.","journal-title":"Indian J Pharmacol"},{"key":"2090_CR49","first-page":"1789","volume":"60","author":"OJ Arola","year":"2000","unstructured":"Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60:1789\u201392.","journal-title":"Cancer Res"},{"key":"2090_CR50","doi-asserted-by":"crossref","unstructured":"Mao Y, Wan J, Lin B, Xu P, Zhang K, Jin M, et al. Felodipine Promotes the Recovery of Mice With Spinal Cord Injury by Activating Macrolipophagy Through the AMPK-mTOR Pathway. J Cell Mol Med. 2025;29:e70543.","DOI":"10.1111\/jcmm.70543"},{"issue":"1","key":"2090_CR51","first-page":"1","volume":"10","author":"FH Siddiqi","year":"2019","unstructured":"Siddiqi FH, Menzies FM, Lopez A, Stamatakou E, Karabiyik C, Ureshino R, et al. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun. 2019;10(1):1\u201314.","journal-title":"Nat Commun"},{"key":"2090_CR52","first-page":"989163","volume":"2010","author":"M Mandal","year":"2010","unstructured":"Mandal M, Jaganathan SK, Mondhe D, Wani ZA, Pal HC. Effect of honey and eugenol on Ehrlich ascites and solid carcinoma. J Biomed Biotechnol. 2010;2010:989163.","journal-title":"J Biomed Biotechnol"},{"key":"2090_CR53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/0253-7613.27022","volume":"38","author":"B Nicol","year":"2006","unstructured":"Nicol B, Prasad S. The effects of cyclophosphamide alone and in combination with ascorbic acid against murine ascites Dalton\u2019s lymphoma. Indian J Pharmacol. 2006;38:260\u20135.","journal-title":"Indian J Pharmacol"},{"key":"2090_CR54","doi-asserted-by":"crossref","unstructured":"Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC. Human Tumor Xenograft Models in NCI Drug Development.  Anticancer Drug Dev. Guid. Humana Press, Totowa, NJ; 1997;101-125.","DOI":"10.1007\/978-1-4615-8152-9_6"},{"key":"2090_CR55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2014.06.041","volume":"472","author":"AM Al-Mahallawi","year":"2014","unstructured":"Al-Mahallawi AM, Khowessah OM, Shoukri RA. Nano-transfersomal ciprofloxacin loaded vesicles for non-invasive trans-tympanic ototopical delivery: in-vitro optimization, ex-vivo permeation studies, and in-vivo assessment. Int J Pharm. 2014;472:304\u201314.","journal-title":"Int J Pharm"},{"key":"2090_CR56","doi-asserted-by":"crossref","first-page":"122274","DOI":"10.1016\/j.ijpharm.2022.122274","volume":"628","author":"P Deng","year":"2022","unstructured":"Deng P, Athary Abdulhaleem MF, Masoud RE, Alamoudi WM, Zakaria MY. Employment of PEGylated ultra-deformable transferosomes for transdermal delivery of tapentadol with boosted bioavailability and analgesic activity in post-surgical pain. Int J Pharm. 2022;628:122274.","journal-title":"Int J Pharm"},{"key":"2090_CR57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molliq.2018.04.058","volume":"261","author":"JS Vankayala","year":"2018","unstructured":"Vankayala JS, Battula SN, Kandasamy R, Mariya GA, Franklin MEE, Pushpadass HA, et al. Surfactants and fatty alcohol based novel nanovesicles for resveratrol: process optimization, characterization and evaluation of functional properties in RAW 264.7 macrophage cells. J Mol Liq. 2018;261:387\u201396.","journal-title":"J Mol Liq"},{"key":"2090_CR58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejps.2019.01.035","volume":"130","author":"Z Sadeghi Ghadi","year":"2019","unstructured":"Sadeghi Ghadi Z, Dinarvand R, Asemi N, Talebpour Amiri F, Ebrahimnejad P. Preparation, characterization and in vivo evaluation of novel hyaluronan containing niosomes tailored by Box-Behnken design to co-encapsulate curcumin and quercetin. Eur J Pharm Sci. 2019;130:234\u201346.","journal-title":"Eur J Pharm Sci"},{"key":"2090_CR59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1061186X.2020.1830408","volume":"29","author":"Z Sadeghi-Ghadi","year":"2021","unstructured":"Sadeghi-Ghadi Z, Ebrahimnejad P, Talebpour Amiri F, Nokhodchi A. Improved oral delivery of quercetin with hyaluronic acid containing niosomes as a promising formulation. J Drug Target. 2021;29:225\u201334.","journal-title":"J Drug Target"},{"key":"2090_CR60","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.2147\/IJN.S109565","volume":"11","author":"A Zeb","year":"2016","unstructured":"Zeb A, Qureshi OS, Kim HS, Cha JH, Kim HS, Kim JK. Improved skin permeation of methotrexate via nanosized ultradeformable liposomes. Int J Nanomedicine. 2016;11:3813\u201324.","journal-title":"Int J Nanomedicine"},{"key":"2090_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10717544.2020.1859000","volume":"28","author":"R Albash","year":"2021","unstructured":"Albash R, Yousry C, Al-Mahallawi AM, Alaa-Eldin AA. Utilization of PEGylated cerosomes for effective topical delivery of fenticonazole nitrate: in-vitro characterization, statistical optimization, and in-vivo assessment. Drug Deliv. 2021;28:1\u20139.","journal-title":"Drug Deliv"},{"key":"2090_CR62","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2010.10.027","volume":"403","author":"YM Hao","year":"2011","unstructured":"Hao YM, Li K. Entrapment and release difference resulting from hydrogen bonding interactions in niosome. Int J Pharm. 2011;403:245\u201353.","journal-title":"Int J Pharm"},{"key":"2090_CR63","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1208\/s12249-017-0710-8","volume":"18","author":"HA Salama","year":"2017","unstructured":"Salama HA, Ghorab M, Mahmoud AA, Abdel Hady M. PLGA nanoparticles as subconjunctival injection for management of glaucoma. AAPS PharmSciTech. 2017;18:2517\u201328.","journal-title":"AAPS PharmSciTech"},{"key":"2090_CR64","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1080\/10717544.2022.2108939","volume":"29","author":"R Albash","year":"2022","unstructured":"Albash R, El-Dahmy RM, Hamed MIA, Darwish KM, Alahdal AM, Kassem AB, et al. Repurposing levocetirizine hydrochloride loaded into cationic ceramide\/phospholipid composite (CCPCs) for management of alopecia: central composite design optimization, in- silico and in-vivo studies. Drug Deliv. 2022;29:2784\u201395.","journal-title":"Drug Deliv"},{"key":"2090_CR65","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40005-024-00693-8","volume":"55","author":"SF Elhabal","year":"2024","unstructured":"Elhabal SF, El-nabarawi MA, Hassanin SO, Hassan FE, Abbas SS, Gebril SM, et al. Transdermal fluocinolone acetonide loaded decorated hyalurosomes cellulose acetate \/ polycaprolactone nanofibers mitigated Freund \u2019 s adjuvant \u2011 induced rheumatoid arthritis in rats. J Pharm Investig. 2024;55:113\u201332.","journal-title":"J Pharm Investig"},{"key":"2090_CR66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/10717544.2020.1858997","volume":"28","author":"AM Fahmy","year":"2021","unstructured":"Fahmy AM, Hassan M, El-Setouhy DA, Tayel SA, Al-Mahallawi AM. Statistical optimization of hyaluronic acid enriched ultradeformable elastosomes for ocular delivery of voriconazole via Box-Behnken design: in vitro characterization and in vivo evaluation. Drug Deliv. 2021;28:77\u201386.","journal-title":"Drug Deliv"},{"key":"2090_CR67","doi-asserted-by":"crossref","first-page":"123259","DOI":"10.1016\/j.ijpharm.2023.123259","volume":"643","author":"MY Zakaria","year":"2023","unstructured":"Zakaria MY, Eraqi WA, Mohamed SA. Ultra-deformable free fatty acid based nano-carriers for topical delivery of Luteolin: a potential paradigm for management of Methicillin-Resistant Staphylococcus aureus skin infections. Int J Pharm. 2023;643:123259.","journal-title":"Int J Pharm"},{"key":"2090_CR68","doi-asserted-by":"crossref","first-page":"101634","DOI":"10.1016\/j.jddst.2020.101634","volume":"57","author":"ZS Rizwanullah","year":"2020","unstructured":"Rizwanullah ZS, Rizwanullah M, Mir SR, Amin S. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: a complete characterization through in vitro, ex-vivo and in vivo assessment. J Drug Deliv Sci Technol. 2020;57:101634.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2090_CR69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.13005\/bpj\/2840","volume":"17","author":"AL Osman","year":"2024","unstructured":"Osman AL, Altoum AEA, Shadroch DF, Babker AMA, Elashmouny H, Hassan NK, et al. Evaluation of the antifungal activity of fluconazole nanovesicles against Aspergillus fumigatus. Biomed Pharmacol J. 2024;17:125\u201334.","journal-title":"Biomed Pharmacol J"},{"key":"2090_CR70","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1080\/10717544.2022.2057619","volume":"29","author":"R Albash","year":"2022","unstructured":"Albash R, Ragaie MH, Hassab MAE, El-Haggar R, Eldehna WM, Al-Rashood ST, et al. Fenticonazole nitrate loaded trans-novasomes for effective management of tinea corporis: design characterization, in silico study, and exploratory clinical appraisal. Drug Deliv. 2022;29:1100.","journal-title":"Drug Deliv"},{"key":"2090_CR71","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.carbpol.2014.08.026","volume":"114","author":"TH Tran","year":"2014","unstructured":"Tran TH, Choi JY, Ramasamy T, Truong DH, Nguyen CN, Choi HG, et al. Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polym. 2014;114:407\u201315.","journal-title":"Carbohydr Polym"},{"key":"2090_CR72","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.2147\/IJN.S213613","volume":"14","author":"R Albash","year":"2019","unstructured":"Albash R, El-Nabarawi MA, Refai H, Abdelbary AA. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Int J Nanomedicine. 2019;14:6555.","journal-title":"Int J Nanomedicine"},{"key":"2090_CR73","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jsps.2022.07.004","volume":"30","author":"AH Elshafeey","year":"2022","unstructured":"Elshafeey AH, El-Dahmy RM. A novel oral medicated jelly for enhancement of etilefrine hydrochloride bioavailability: in vitro characterization and pharmacokinetic evaluation in healthy human volunteers. Saudi Pharm J. 2022;30:1435\u201347.","journal-title":"Saudi Pharm J"},{"key":"2090_CR74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2016.01.034","volume":"225","author":"P Fonte","year":"2016","unstructured":"Fonte P, Reis S, Sarmento B. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. J Control Release. 2016;225:75\u201386.","journal-title":"J Control Release"},{"key":"2090_CR75","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.jddst.2021.102424","volume":"62","author":"AM Abdelhaleem Ali","year":"2021","unstructured":"Abdelhaleem Ali AM, Abo El-Enin HA. In-vitro\/in-vivo evaluation of paclitaxel freeze-dried micellar nanoparticles intended for buccal delivery. J Drug Deliv Sci Technol. 2021;62:102424.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2090_CR76","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/jps.23146","volume":"101","author":"D Psimadas","year":"2012","unstructured":"Psimadas D, Georgoulias P, Valotassiou V, Loudos G. Enhancement of felodipine dissolution rate through its Incorporation into Eudragit R? E\u2013PHB polymeric microparticles: invitro characterization and investigation of absorption in rats. J Pharm Sci. 2012;101:2271\u201380.","journal-title":"J Pharm Sci"},{"key":"2090_CR77","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13318-013-0158-5","volume":"39","author":"BP Sahu","year":"2014","unstructured":"Sahu BP, Das MK. Preparation and in vitro\/in vivo evaluation of felodipine nanosuspension. Eur J Drug Metab Pharmacokinet. 2014;39:183\u201393.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2090_CR78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpb.2006.12.003","volume":"66","author":"P Sriamornsak","year":"2007","unstructured":"Sriamornsak P, Thirawong N, Korkerd K. Swelling, erosion and release behavior of alginate-based matrix tablets. Eur J Pharm Biopharm. 2007;66:435\u201350.","journal-title":"Eur J Pharm Biopharm"},{"key":"2090_CR79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S289828","volume":"16","author":"E Alaaeldin","year":"2021","unstructured":"Alaaeldin E, Abou-Taleb HA, Mohamad SA, Elrehany M, Gaber SS, Mansour HF. Topical nano-vesicular spanlastics of celecoxib: enhanced anti-inflammatory effect and down-regulation of tnf-\u03b1, nf-\u043ab and cox-2 in complete freund\u2019s adjuvant-induced arthritis model in rats. Int J Nanomedicine. 2021;16:133\u201345.","journal-title":"Int J Nanomedicine"},{"key":"2090_CR80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.colsurfb.2010.07.020","volume":"81","author":"AP Nayak","year":"2010","unstructured":"Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces. 2010;81:263\u201373.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2090_CR81","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/CMAR.S228718","volume":"12","author":"BS Wong","year":"2020","unstructured":"Wong BS, Chiu LY, Tu DG, Sheu GT, Chan TT. Anticancer effects of antihypertensive L-type calcium channel blockers on chemoresistant lung cancer cells via autophagy and apoptosis. Cancer Manag Res. 2020;12:1913.","journal-title":"Cancer Manag Res"},{"key":"2090_CR82","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2016.02.051","volume":"81","author":"F Hanif","year":"2016","unstructured":"Hanif F, Perveen K, Malhi SM, Simjee SU. Calcium channel blocker increases the anticancer activity of temozolomide by inhibiting autocrine VEGF signaling. J Pharmacol Toxicol Methods. 2016;81: 350.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2090_CR83","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2021.105152","volume":"74","author":"P Panneerpandian","year":"2021","unstructured":"Panneerpandian P, Rao DB, Ganesan K. Calcium channel blockers lercanidipine and amlodipine inhibit YY1\/ERK\/TGF-\u03b2 mediated transcription and sensitize the gastric cancer cells to doxorubicin. Toxicol In Vitro. 2021;74: 105152.","journal-title":"Toxicol In Vitro"},{"key":"2090_CR84","first-page":"3617","volume":"48","author":"KR Huber","year":"1988","unstructured":"Huber KR, Schmidt WF, Ettinger RS, Neuberg RW. Antiproliferative effect of verapamil alone on brain tumor cells in vitro. Cancer Res. 1988;48:3617\u201321.","journal-title":"Cancer Res"},{"key":"2090_CR85","doi-asserted-by":"crossref","first-page":"902305","DOI":"10.3389\/fphar.2022.902305","volume":"13","author":"B Fu","year":"2022","unstructured":"Fu B, Dou X, Zou M, Lu H, Wang K, Liu Q, et al. Anticancer effects of amlodipine alone or in combination with gefitinib in non-small cell lung cancer. Front Pharmacol. 2022;13:902305.","journal-title":"Front Pharmacol"},{"key":"2090_CR86","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1177\/0960327120930266","volume":"39","author":"HE Abo Mansour","year":"2020","unstructured":"Abo Mansour HE, El-Batsh MM, Badawy NS, Mehanna ET, Mesbah NM, Abo-Elmatty DM. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice. Hum Exp Toxicol. 2020;39:1528\u201344.","journal-title":"Hum Exp Toxicol"},{"key":"2090_CR87","first-page":"1","volume":"16","author":"MAY Alqudah","year":"2022","unstructured":"Alqudah MAY, Al-Samman R, Azaizeh M, Alzoubi KH. Amlodipine inhibits proliferation, invasion, and colony formation of breast cancer cells. Biomed Rep. 2022;16:1\u20137.","journal-title":"Biomed Rep"},{"key":"2090_CR88","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bcp.2019.04.026","volume":"164","author":"J Dewangan","year":"2019","unstructured":"Dewangan J, Srivastava S, Mishra S, Divakar A, Kumar S, Rath SK. Salinomycin inhibits breast cancer progression via targeting HIF-1\u03b1\/VEGF mediated tumor angiogenesis in vitro and in vivo. Biochem Pharmacol. 2019;164:326\u201335.","journal-title":"Biochem Pharmacol"},{"key":"2090_CR89","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s43032-025-01913-8","volume":"32","author":"E Kocal","year":"2025","unstructured":"Kocal E, Atilgan R, Pala \u015e, Aslan M, Kulo\u011flu T, Ilhan N, et al. Effect of Nifedipine in preventing ovarian hyperstimulation syndrome through TRPC1 ion channel inhibition. Reprod Sci. 2025;32:2375\u201387.","journal-title":"Reprod Sci"},{"key":"2090_CR90","doi-asserted-by":"crossref","first-page":"31666","DOI":"10.1074\/jbc.R112.343061","volume":"287","author":"GR Monteith","year":"2012","unstructured":"Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem. 2012;287:31666.","journal-title":"J Biol Chem"},{"key":"2090_CR91","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrc3105","volume":"11","author":"N Prevarskaya","year":"2011","unstructured":"Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011;11:609\u201318.","journal-title":"Nat Rev Cancer"},{"key":"2090_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111366","author":"F Sadras","year":"2021","unstructured":"Sadras F, Monteith GR, Roberts-Thomson SJ. An emerging role for calcium signaling in cancer-associated fibroblasts. Int J Mol Sci. 2021;22:11366. https:\/\/doi.org\/10.3390\/ijms222111366.","journal-title":"Int J Mol Sci"},{"key":"2090_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08037051.2019.1568182","volume":"28","author":"M Burnier","year":"2019","unstructured":"Burnier M, Narkiewicz K, Kjeldsen SE, Oparil S. New data on antihypertensive drugs and risk of cancer: should we worry? Blood Press. 2019;28:1\u20133.","journal-title":"Blood Press"},{"key":"2090_CR94","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/pds.3645","volume":"23","author":"Q Chen","year":"2014","unstructured":"Chen Q, Zhang Q, Zhong F, Guo S, Jin Z, Shi W, et al. Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2014;23:711\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2090_CR95","doi-asserted-by":"crossref","unstructured":"Grimaldi-Bensouda L, Klungel O, Kurz X, De Groot MCH, Afonso ASM, De Bruin ML, et al. Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open. 2016;6:e009147.","DOI":"10.1136\/bmjopen-2015-009147"},{"key":"2090_CR96","doi-asserted-by":"crossref","first-page":"62545","DOI":"10.18632\/oncotarget.19117","volume":"8","author":"H Ni","year":"2017","unstructured":"Ni H, Rui Q, Zhu X, Yu Z, Gao R, Liu H. Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8:62545.","journal-title":"Oncotarget"},{"key":"2090_CR97","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13297","volume":"7","author":"G Jacquemet","year":"2016","unstructured":"Jacquemet G, Baghirov H, Georgiadou M, Sihto H, Peuhu E, Cettour-Janet P, et al. L-type calcium channels regulate filopodia stability and cancer cell invasion downstream of integrin signalling. Nat Commun. 2016;7: 13297.","journal-title":"Nat Commun"},{"key":"2090_CR98","doi-asserted-by":"crossref","unstructured":"Liang SY, Xiao HK. The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC. Open Med. 2023;18:20230801.","DOI":"10.1515\/med-2023-0801"},{"key":"2090_CR99","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/acs.nanolett.7b00021","volume":"17","author":"JL Perry","year":"2017","unstructured":"Perry JL, Reuter KG, Luft JC, Pecot CV, Zamboni W, DeSimone JM. Mediating passive tumor accumulation through particle size, tumor type, and location. Nano Lett. 2017;17:2879\u201386.","journal-title":"Nano Lett"},{"key":"2090_CR100","first-page":"929","volume":"11","author":"H Bao","year":"2016","unstructured":"Bao H, Zhang Q, Xu H, Yan Z. Effects of nanoparticle size on antitumor activity of 10-hydroxycamptothecin-conjugated gold nanoparticles: in vitro and in vivo studies. Int J Nanomedicine. 2016;11:929\u201340.","journal-title":"Int J Nanomedicine"},{"key":"2090_CR101","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.bpj.2009.07.009","volume":"97","author":"O Lieleg","year":"2009","unstructured":"Lieleg O, Baumg\u00e4rtel RM, Bausch AR. Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J. 2009;97:1569\u201377.","journal-title":"Biophys J"},{"key":"2090_CR102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2016.09.004","volume":"244","author":"DL Priwitaningrum","year":"2016","unstructured":"Priwitaningrum DL, Blond\u00e9 JBG, Sridhar A, van Baarlen J, Hennink WE, Storm G, et al. Tumor stroma-containing 3D spheroid arrays: a tool to study nanoparticle penetration. J Control Release. 2016;244:257\u201368.","journal-title":"J Control Release"},{"key":"2090_CR103","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1039\/C4BM00323C","volume":"3","author":"H Lu","year":"2015","unstructured":"Lu H, Utama RH, Kitiyotsawat U, Babiuch K, Jiang Y, Stenzel MH. Enhanced transcellular penetration and drug delivery by crosslinked polymeric micelles into pancreatic multicellular tumor spheroids. Biomater Sci. 2015;3:1085\u201395.","journal-title":"Biomater Sci"},{"key":"2090_CR104","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.colsurfb.2018.10.041","volume":"173","author":"E Mazzotta","year":"2019","unstructured":"Mazzotta E, Oliviero Rossi C, Muzzalupo R. Different BRIJ97 colloid systems as potential enhancers of acyclovir skin permeation and depot. Colloids Surf B Biointerfaces. 2019;173:623\u201331.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2090_CR105","volume":"12","author":"C Karthika","year":"2022","unstructured":"Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S, et al. Multidrug resistance of cancer cells and the vital role of P-Glycoprotein. Life (Basel, Switzerland). 2022;12: 897.","journal-title":"Life (Basel, Switzerland)"},{"key":"2090_CR106","first-page":"1967","volume":"41","author":"T Tsuruo","year":"1981","unstructured":"Tsuruo T, Iida H, Tsukagoshi SSY. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967\u201372.","journal-title":"Cancer Res"},{"key":"2090_CR107","doi-asserted-by":"crossref","unstructured":"Zhou J, Wang N, Lin YK, Li QL, Liu RM, Hu JQ, et al. Targeting NFAT2 for Reversing the P-gp-Mediated Multidrug Resistance to Paclitaxel by Manidipine. Cancers (Basel). 2025;17:3289.","DOI":"10.3390\/cancers17203289"},{"key":"2090_CR108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbrc.2015.01.137","volume":"460","author":"S Orrenius","year":"2015","unstructured":"Orrenius S, Gogvadze V, Zhivotovsky B. Calcium and mitochondria in the regulation of cell death. Biochem Biophys Res Commun. 2015;460:72\u201381.","journal-title":"Biochem Biophys Res Commun"},{"key":"2090_CR109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185\u2013229.","journal-title":"Pharmacol Rev"},{"key":"2090_CR110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4291\/wjgp.v6.i4.235","volume":"6","author":"S Tingle","year":"2015","unstructured":"Tingle S, Moir J, White S. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol. 2015;6:235.","journal-title":"World J Gastrointest Pathophysiol"},{"key":"2090_CR111","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/CAD.0000000000000947","volume":"31","author":"SJ Tingle","year":"2020","unstructured":"Tingle SJ, Severs GR, Moir JAG, White SA. Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study. Anticancer Drugs. 2020;31:737\u201341.","journal-title":"Anticancer Drugs"},{"key":"2090_CR112","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","volume":"5","author":"F Alexis","year":"2008","unstructured":"Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505\u201315.","journal-title":"Mol Pharm"},{"key":"2090_CR113","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","volume":"9","author":"RA Petros","year":"2010","unstructured":"Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615\u201327.","journal-title":"Nat Rev Drug Discov"},{"key":"2090_CR114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae - The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334.","journal-title":"J Control Release"},{"key":"2090_CR115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"O Tacar","year":"2013","unstructured":"Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65:157\u201370.","journal-title":"J Pharm Pharmacol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02090-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:49:17Z","timestamp":1775490557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02090-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":115,"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02090-0","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study\u2019s in vivo protocol was approved by the Institutional Ethics Committee of the Faculty of Pharmacy, Cairo University (Approval Number: PI 2999).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors reviewed and approved the final manuscript and agreed with the submission and publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}